Search
Economic evaluation analysis indicated imbalance in pediatric cancer treatment
- OPACC
- Feb 5, 2013
- 1 min read
Applying economic evaluation tools, such as cost and cost-effectiveness analysis, to pediatric cancer treatments demonstrated an imbalance of tumor-directed therapy and supportive therapy evaluations, according to a recent literature review.
Read more here.
Recent Posts
See AllWhile the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...
Untreated growth hormone deficiency was associated with neurocognitive impairment and reduced physical functioning among adult survivors...